CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology - 43(2022), 9 vom: 26. Sept., Seite 5763-5764 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Schiano di Cola, Francesca [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 19.08.2022 Date Revised 24.08.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10072-022-06154-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341412619 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341412619 | ||
| 003 | DE-627 | ||
| 005 | 20231226011721.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10072-022-06154-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1137.xml |
| 035 | |a (DE-627)NLM341412619 | ||
| 035 | |a (NLM)35618933 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Schiano di Cola, Francesca |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.08.2022 | ||
| 500 | |a Date Revised 24.08.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a CGRP | |
| 650 | 4 | |a Disability | |
| 650 | 4 | |a Erenumab | |
| 650 | 4 | |a Migraine | |
| 650 | 4 | |a Prophylaxis | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents, Immunological |2 NLM | |
| 650 | 7 | |a Calcitonin Gene-Related Peptide Receptor Antagonists |2 NLM | |
| 650 | 7 | |a Calcitonin Gene-Related Peptide |2 NLM | |
| 650 | 7 | |a JHB2QIZ69Z |2 NLM | |
| 700 | 1 | |a Caratozzolo, Salvatore |e verfasserin |4 aut | |
| 700 | 1 | |a Bolchini, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Ceccardi, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Cortinovis, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Liberini, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Padovani, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Rao, Renata |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology |d 2000 |g 43(2022), 9 vom: 26. Sept., Seite 5763-5764 |w (DE-627)NLM108608468 |x 1590-3478 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2022 |g number:9 |g day:26 |g month:09 |g pages:5763-5764 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10072-022-06154-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2022 |e 9 |b 26 |c 09 |h 5763-5764 | ||